Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis

Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12.

Abstract

Tuberculosis has become a great global public health threat. Compared with drug-susceptible tuberculosis (TB), the treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) involve more severe adverse events and poorer treatment outcomes. Linezolid (LZD) is the first oxazolidinones used for TB. Thanks to its potent activity against Mycobacterium tuberculosis, LZD has become one of the key agents in the regimens against MDR/XDR-TB. However, this drug may cause intolerability and other adverse events. Contezolid, another novel oxazolidinone, can also inhibit M. tuberculosis, still with fewer adverse effects compared with LZD. This paper is to prospect the potentials of contezolid in the treatment of MDR/XDR-TB, with focus on its efficacy and possible adverse effects.

Keywords: MDR-TB; Mycobacterium tuberculosis; XDR-TB; contezolid.

MeSH terms

  • Antitubercular Agents / adverse effects
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Extensively Drug-Resistant Tuberculosis* / microbiology
  • Humans
  • Linezolid / adverse effects
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis*
  • Oxazolidinones* / adverse effects
  • Pyridones
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / microbiology

Substances

  • Antitubercular Agents
  • Oxazolidinones
  • Pyridones
  • contezolid
  • Linezolid